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Norbormide (NRB, 5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-
pyridylbenzylidene)-5-norbornene-2,3-dicarboximide) is a synthetic
compound introduced as a speciﬁc rat toxicant in 1964 [1]. It is
endowed with unique pharmacodynamic properties inducing
species-selective contraction of rat peripheral blood vessels, likelyby acting on a phospholipase C (PLC)-coupled receptor, which is
abundantly or exclusively expressed in the myocytes of these vessels
[2]. NRB instead elicits a relaxing action in rat aorta and non-vascular
smooth muscles, as well as in blood vessels of species other than the
rat, possibly because of reduced Ca2+ inﬂux through voltage-
dependent L-type Ca2+ channels [1–7]. NRB is a mixture of eight
racemic stereoisomers, which differ in their vasoconstrictor activity
and toxicity [8–10]. Detailed studies of each individual stereoisomer
demonstrate that both drug-induced contractile activity and lethality
in rats are strongly stereospeciﬁc, with only the endo conﬁgurations
retaining the effects elicited by the mixture [8]. Moreover, investiga-
tions over a series of NRB fragments derived from the “deconstruc-
tion” of the parent molecule suggest that integrity of the molecule
must be retained, in order for NRB-type vasoconstriction to be con-
served [11].
Intriguingly, NRB also causes rat-selective mitochondrial dysfunc-
tion that can be traced to opening of the permeability transition (PT)
pore (PTP) [12,13]. The PTP is a high conductance channel of the inner
mitochondrial membrane (IMM), whose opening leads to an increase
of permeability to ions and solutes with an exclusion size of about
1500 Da. This potentially catastrophic event has long been known,
yet the molecular bases for its occurrence remain unsolved despite
its established importance in several in vivo models of pathology
[14–17]. The key structural feature responsible for PTP activation by
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lationship between lethal vasoconstriction and the PTP-inducing
effect is not obvious, because both lethal (endo-) and non lethal
(exo-) NRB isomers display comparable stimulatory effects on the
PT in isolated mitochondria [13].
In order to better understand the mode of action of NRB, and the
possible correlation between the various rat-selective effects, this
study examines the mechanisms causing species-speciﬁcity for PTP
activation. It has already been shown that rat selectivity of NRB toward
the PT is not due to a different PTP structure/target in the various animal
species, but rather involves a transport system allowing selective
penetration of the drug in the IMM/matrix of rat mitochondria
[12,13]. Indeed, the cationic NRB derivative 5-(α-hydroxy-α-2-pyridyl-
benzyl)-7-(N-pivaloyloxymethyl-α-2-pyridylbenzylydene)-5-norbor-
nene-2,3-dicarboximide (OL14), which permeates through the IMM
driven by the inside negative membrane potential, is as effective in
mouse and guinea pig as it is in rat mitochondria [13]. The present
paper reports on whether the putative NRB carrier is located in the
outer mitochondrial membrane (OMM) by comparing the PTP-
regulatory properties of the drug in mitochondria and in digitonin-
treated mitoplasts. Our data demonstrate that an intact OMM is neces-
sary for the PTP-inducing effects of NRB, and strongly suggest that the
drug permeates through domains of the 18 kDa translocator protein
(TSPO, formerly known as peripheral benzodiazepine receptor, [18]),
or of TSPO-associated protein(s), that are unique to the rat.
2. Materials and methods
NRB was purchased from I.N.D.I.A. Industria Chimica, Padova while
its cationic derivative OL14 was synthesized and puriﬁed by Drs.
David Rennison and Olivia Laita, Department of Chemistry,
University of Auckland (New Zealand). The structure of these com-
pounds is depicted in Fig. 1. Hematoporhyrin IX, protoporphyrin IX,
deuteroporphyrin IX, and coproporphyrin III were obtained from Fron-
tier Scientiﬁc (Logan, UT, U.S.A.) and stock solutions were prepared in
dimethylsulfoxide. N,N-dihexyl-2-(4-ﬂuorophenyl)indole-3-acetamide
(FGIN1-27), (4′-chlorodiazepam;7-chloro-5-(4-chlorophenyl)-1,3-
dihydro-1-methyl-2H-1,4-benzodiazepin-2-one) (Ro5-4864), digito-
nin, phenylarsine oxide (PhAsO) and etioporphyrin I were purchased
from Sigma. Copper-o-phenanthroline (Cu(OP)2) was prepared just be-
fore use by mixing CuSO4 with o-phenanthroline in a molar ratio of 1:2
in bidistilled water. All chemicals were of the highest purity commer-
cially available.
Liver mitochondria from Albino Wistar rats, CD1 mice and Albino
guinea pigs (from Charles River, Italy) were prepared by standard dif-
ferential centrifugation. The ﬁnal pellet was suspended in 0.25 M
sucrose to give a protein concentration of 80-100 mg/ml, as measured
by the biuret method. The quality of mitochondrial preparations was
established by the value of the respiratory control ratio (RCR), as
described previously [13].
Mitoplasts were prepared by treatment of mitochondria with
0.09 mg of digitonin/mg of mitochondrial protein, and purity of theFig. 1. Chemical structures of NRB and OL14.preparations was checked by enzymatic and electron microscopy as-
says, as described in detail in Ref. [19].
Mitochondrial PT was induced at 25 °C in a standard medium
(250 mM sucrose, 10 mM Tris-Mops pH 7.4, 5 mM succinate-Tris,
1 mM Pi-Tris, 10 μM EGTA-Tris, 1 μM rotenone, 0.5 μg/ml oligomycin).
Ca2+, phenylarsine oxide (PhAsO) and Cu(OP)2 were used as PT in-
ducers. PT-induced osmotic swelling of mitochondrial suspensions
was followed as the decrease in 90° light scattering at 540 nm,
measured with a Perkin-Elmer LS 50 spectrophotoﬂuorimeter [12].
Permeabilization rates were calculated as the rate of change of light
scattering immediately after addition of inducer. The calcium
retention capacity (CRC), i.e., the amount of Ca2+ accumulated and
retained by mitochondria before the occurrence of the PT [20] was
measured with 0.5 μM Calcium Green-5N as an indicator of the Ca2+
concentration in the external medium (excitation at 480 nm and
emission at 530 nm) [13].
3. Results
3.1. Effects of NRB and OL14 on the mitochondrial and mitoplast PT
We compared the effects of NRB and its cationic derivative, OL14,
on mitochondria and mitoplasts prepared by extraction with 0.09 mg
digitonin×mg−1 of protein, i.e. a condition yielding mitoplasts that
maintain a high IMM integrity as assessed by development of a mem-
brane potential, ability to take up Ca2+, and maintenance of a perme-
ability barrier to solutes [19]. We tested the ability of both organelles
to undergo the PT with the sensitive calcium retention capacity (CRC)
test, which measures the threshold Ca2+ load required to open the
pore. Incubation of mitochondria with 40 nmol/mg protein of NRB
for 5 min decreased the Ca2+ load required for PTP opening without
affecting the rate of Ca2+ uptake (Fig. 2A trace b, compare with
trace a), an effect that was also seen with OL14 (Fig. 2A, trace c). In
striking contrast, NRB did not affect the CRC in mitoplasts (Fig. 2A′,
trace b, compare with trace a) while OL14 was as effective as it was
in mitochondria. The concentration-dependence of the effects of
NRB and OL14 in mitochondria and mitoplasts is presented in Fig. 3.
These ﬁndings indicate that NRB requires an intact OMM to be effec-
tive; yet its site of action must be at the IMM or matrix, because its
PTP-inducing effects in mitochondria are retained by the permeant
cationic OL14 (see also Refs. [12,13]). The higher doses necessary to
induce PT activation in mitoplasts suggest that access of OL14 to the
mitochondrial matrix is also facilitated by the OMM.
We next tested if the differential effects of NRB on PTP in mito-
chondria and mitoplasts could also be detected by modifying two
classes of IMM (matrix- and surface-exposed) PT-regulating sulfhy-
dryls, which can be discriminated based on their reactivity with the
membrane-permeant dithiol cross-linker phenylarsine oxide
(PhAsO) and the membrane-impermeant thiol oxidant copper-o-
phenanthroline (Cu(OP)2), respectively [21–23]. We ﬁrst assessed
the response to PhAsO. In these protocols, a permissive Ca2+ load
that does not cause PTP opening per se was allowed to accumulate
ﬁrst (Fig. 4A, A′, trace a); ruthenium red (RR) was then added to pre-
vent Ca2+ redistribution, and ﬁnally PTP opening was triggered by
PhAsO and the process was monitored as the ensuing Ca2+ release
(Fig. 4A, A′, trace b), which was indeed fully inhibited by CsA
(Fig. 4A, A′, trace c). Treatment with NRB caused an earlier onset of
PTP opening in mitochondria (Fig. 4A, trace d) but not in mitoplasts,
where the release rate was indistinguishable from that of PhAsO
alone (Fig. 4A′, trace d). Consistent with what was observed with
Ca2+-dependent PT (Figs. 2, 3), OL14 caused PhAsO to induce imme-
diate triggering of PTP opening in both preparations (Fig. 4A, A′, trace e).
The response to Cu(OP)2 gave results superimposable to those obtained
with PhAsO, as PTP openingwas stimulated byNRB inmitochondria but
not in mitoplasts, while OL14 was equally effective (Fig. 4B, B′, trace
labeling is identical to panels A, A′).
Fig. 2. Effects of NRB and OL14 on the Ca2+ retention capacity of rat liver mitochondria
and mitoplasts. One milligram per milliliter of rat liver mitochondria (A) or mitoplasts
(A′) was suspended in the standard incubation medium in the presence of 0.5 μM Cal-
cium Green-5N, then loaded with a train of 10 (A) or 5 (A′) μM Ca2+ pulses at 1-min
intervals (trace a). In traces b,c the organelles were preincubated for 5 min with
40 nmol/mg of NRB (b) or OL14 (c). Extramitochondrial Ca2+ was monitored as the
ﬂuorescence emission of Calcium Green-5N (λexcitation=480 nm; λemission=530 nm).
Fig. 4. Effects of NRB and OL14 on PT-dependent Ca2+ release in rat liver mitochondria
and mitoplasts. One milligram per milliliter of rat liver mitochondria (A) or mitoplasts
(A′) was incubated in the standard medium containing 0.5 μM Calcium Green-5N and
allowed to accumulate a Ca2+ load (30 and 15 nmol/mg of protein, respectively) that
was not sufﬁcient for spontaneous PTP opening (trace a). PTP opening was then trig-
gered by 5 μM PhAsO (traces b–e). In the experiments of trace c 1 μM CsA was also pre-
sent, and in those of traces d and e the organelles were supplemented with 40 nmol/
mg of NRB and OL14, respectively, and incubated for 5 min prior to the addition of
Ca2+. Where indicated, Ca2+ was added followed by 0.1 μM ruthenium red (RR) and
by PhAsO. B, B′, the experimental conditions were the same as those described in A,
A′, except that 3 μM Cu(OP)2 was used as PT inducer.
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ence of high afﬁnity TSPO-ligands
It has been previously demonstrated that the OMM regulates the
PT and that PTP regulatory sites are contributed by TSPO [19]. To
test whether NRB transport could occur through TSPO we studied
the effects of NRB on the PT induced by PhAsO and Cu(OP)2 in the
presence or absence of hematoporphyrin IX (HP), a dicarboxylic por-
phyrin with high afﬁnity for TSPO that at the concentration used here
(3 μM) does not affect the PTP per se [19,21,24]. Mitochondria were
incubated with NRB for 5 or 2 min depending on whether PhAsO or
Cu(OP)2 was used as PT inducer because at these incubation times
NRB displayed the maximal effect with each thiol reagent (data not
shown). To evaluate the extent of stimulation by NRB, the permeabi-
lization rates of NRB-treated mitochondria were normalized to those
of NRB-untreated mitochondria. In the case of PhAsO HP suppressed
the stimulatory effect of NRB up to 25–30 nmol/mg (Fig. 5A). The
effect was even larger in the case of PTP induction by Cu(OP)2,
where HP caused a marked inhibition of the PT up to 20–30 nmol/mg
NRB (Fig. 5B). Consistent with competition for TSPO binding, NRB
above 20–30 nmol/mg regained its potentiating ability on the PTP.
Similar effects have been observed in the presence of other proto-
porphyrin IX-like dicarboxylic porphyrins, such as deuteroporphyrin
IX and protoporphyrin IX itself, which display even higher afﬁnity
than HP in binding TSPO [24]. However, in this study no effect onFig. 3. CRC of rat liver mitochondria andmitoplasts loaded with NRB and OL14. The CRC
was calculated according to the experimental procedure described in the legend to
Fig. 2 after the addition of NRB (A) or OL14 (B) to rat liver mitochondria (closed sym-
bols) or mitoplasts (open symbols). PTP opening was determined as the Ca2+ retention
capacity (CRC, expressed as the % of the CRC of organelles not treated with NRB or
OL14). Values are mean±S.D. of three experiments.the NRB-stimulated PT was observed with PP-unrelated porphyrins,
such as the tetracarboxylic coproporphyrin III, whose binding to
TSPO is very weak, or etioporphyrin I, which lacks carboxylic groups
(data not shown). These results suggest that, at low NRB concentra-
tions, interference between NRB and TSPO-porphyrin binding sites
causes (i) a drop of reactivity of the external thiols, and (ii) blockade
of drug translocation into internal PTP-regulating sites. Other selec-
tive TSPO-ligands, such as Ro5-4864 and FGIN1-27 [18,25,26], at con-
centrations (≤10 μM) not sufﬁcient to induce the PT per se (data notFig. 5. Effects of NRB and their inhibition by HP, on the PT induced by PhAsO and Cu
(OP)2 in rat liver mitochondria. Mitochondria (0.5 mg/ml) were incubated with the in-
dicated concentrations of NRB for 5 min (panel A) or 2 min (panel B) in standard me-
dium at 25 °C, both in the absence (no HP) or presence (HP) of 3 μM HP; then 10 μM
Ca2+ (a Ca2+ pulse not sufﬁcient to induce the PT per se) was added followed by
5 μM PhAsO (A) or 3 μM Cu(OP)2 (B). Spreading of the PT was followed as the decrease
in light scattering intensity at 540 nm. The data are expressed as the ratio between the
permeabilization rates of NRB-treated (Pr) and -untreated (Pr0) mitochondria. Values
are mean±S.D. of three experiments.
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effects of NRB on the PT induced by both PhAsO and Cu(OP)2
(Fig. 6). In summary, these results suggest that in the presence of spe-
ciﬁc TSPO-ligands NRB accumulates in the contact regions between
IMM and OMM, and perturbation of these regions does not allow
NRB to reach its sites of action at the IMM/matrix.
The experiments described above were performed also in mouse
and guinea pig liver mitochondria. Irrespective of whether PhAsO or
Cu(OP)2 was used, or whether TSPO ligands were present, no effect
of NRB was observed, while the PT could be induced by the positively
charged OL14 (results not shown). These data conﬁrm that in animal
species different from the rat the drug-sensitive sites of the mito-
chondrial PTP are not accessible to NRB [12,13].
4. Discussion
In this paper we have demonstrated that rat-selective opening of
the PTP by NRB in liver mitochondria requires an intact OMM, and
obtained compelling evidence that the effect of NRB is speciﬁcally
mediated by the OMM protein, TSPO.
The regulatory role of the OMM is demonstrated by the lack of PT-
promoting effect of NRB in mitoplasts, i.e. in the absence of an intact
OMM irrespective of whether PTP opening is induced by Ca2+ plus Pi,
or by reaction with internal (PhAsO-sensitive) or external (Cu(OP)2-
sensitive) sulfhydryls. We deduce that in rat mitochondria NRB is
transferred from the OMM to the IMM through a transport system
that is lost in mitoplasts. OMM TSPO appears to be the key element
mediating mitochondrial internalization of NRB, as suggested by the
ﬁndings that, at NRB concentrations up to 30 μM (i) high-afﬁnity li-
gands of TSPO, such as protoporphyrin IX-like dicarboxylic porphy-
rins, Ro5-4864 and FGIN1-27, are able to abolish the effects of NRB
at the internal, PhAsO-reactive sites; and (ii) co-administration of
porphyrins and NRB to mitochondria drastically reduces the reactivi-
ty of the external, Cu(OP)2-sensitive sites, which we know to be in
close contact with the binding site of porphyrins on TSPO [19].
These effects are likely a consequence of competition between NRB
and TSPO-ligands for speciﬁc sites on TSPO, which both alters the ex-
ternal, Cu(OP)2-sensitive PTP domains and prevents NRB transfer to
the matrix. These ﬁndings suggest that NRB interacts with TSPO
sites adjacent to or overlapping with those of porphyrins, Ro5-4864
and FGIN1-27.
The cationic OL14 is active on both mitochondria and mitoplasts of
all species and is more potent than NRB. These data suggest that both
agents act from the matrix and thus must cross both the OMM and
IMM. Indeed, NRB cationic derivatives transiently depolarize the mi-
tochondrial inner membrane and then activate the PT also in mouseFig. 6. Effects of NRB, and their inhibition by Ro5-4864 and FGIN1-27, on the PT in-
duced by PhAsO and Cu(OP)2 in rat liver mitochondria. Mitochondria (1 mg/ml) sus-
pended in the standard medium at 25 °C were loaded with a small Ca2+ load
(10 μM) that was not sufﬁcient for spontaneous PTP opening (trace a) followed by
5 μM PhAsO (A, traces b–e) or 3 μM Cu(OP)2 (B, traces b–e). In traces c–e, mitochondria
were supplemented with 10 (A) or 30 (B) nmol/mg NRB, and with the TSPO ligand
Ro5-4864 (10 μM, trace d only) or FGIN1-27 (10 μM, trace e only). The PT was followed
as the decrease in light scattering intensity at 540 nm.and guinea pig, consistent with transport to the matrix [13]. It is
also noteworthy that cationic NRB derivatives that do not bear the ac-
tive core still depolarize the inner membrane but are not able to acti-
vate the PT [13]. But why should NRB require TSPO to get to the IMM
and not OL14? We think that the amount of (neutral) NRB taken up
by mitochondria via passive diffusion may not be sufﬁcient to stimu-
late the PT unless the drug ﬁrst binds the OMM (via TSPO) and then is
transferred to the IMM. It is not inconceivable that the cationic OL14
can instead be attracted by the huge driving force provided by the
IMM proton electrochemical gradient (predicted equilibrium accu-
mulation of 1000 if the membrane potential is −180 mV, negative
inside).
When administered to mitochondria at 30 nmol/mg protein or
more, NRB regains its ability to potentiate the PT irrespective of the
presence of selective TSPO-ligands. TSPO is still required, because
these concentrations of NRB do not affect the PT in mitoplasts. A likely
explanation is that NRB at high concentrations is able to bind to lower
afﬁnity secondary sites on TSPO, overcoming the inhibition produced
by TSPO ligands occupying the primary binding site. The presence of
two populations of (high and low afﬁnity) drug-binding sites is com-
mon to other TSPO-ligands, and this observation has been used to ex-
plain the dose-dependent pro-apoptotic and anti-apoptotic effects,
and modulation of muscle contractility of many TSPO-ligands
[27–31]. Although in our interpretation TSPO allows NRB to be trans-
ported to its internal matrix site(s) of action (see also Ref. [13]), we
cannot exclude that, after interaction with NRB, TSPO per se might
mediate PTP opening.
In conclusion, the present data support previous results demon-
strating a key role of TSPO in PT regulation [19,32]. The absence of de-
monstrable effects of NRB on the PTP of mouse and guinea pig
mitochondria suggests that selectivity may depend on one or more
residues of TSPO that are unique to the rat. Of note, and in spite of
the high degree of TSPO sequence homology, changes in only 3
amino acid residues cause remarkable differences in the binding po-
tency of the archetypal TSPO-ligand Ro5-4864 in different species
[33–36], and mutation of only one critical residue at the interface be-
tween OMM and cytoplasm results in complete loss of ligand binding
activity [37].
Alignment of the rat and mouse primary sequences revealed that
the proteins have a high level of identity, with only 8 amino acid sub-
stitutions (Fig. 7). Since mouse and guinea pig are both resistant to
NRB, amino acids that have changed during evolution between
these species should not be critical. If this hypothesis is correct, the
only relevant difference between the NRB-sensitive rat and NRB-
insensitive mouse and guinea pig would be at position 113, where
in the rat a methionine interrupts a stretch of 3 leucine residues with-
in a highly conserved DLLLVSG motif (Fig. 7A). We analyzed all NRB-
insensitive species [3] and found that, as well as mouse and guinea
pig, the LLL sequence is conserved in ox, cat, chicken, dog, horse,
monkey, rabbit, and sheep. Based on the predicted protein membrane
topology [38] the DLLLVSG motif is located at the interface between
the OMM and the cytosol (Fig. 7B), where it could serve as a selectiv-
ity ﬁlter for the transported species. This issue can be addressed by
proper receptor swap and mutagenesis experiments that are under
way in our laboratories.Acknowledgements
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Fig. 7. Comparison of the primary sequence of rat, mouse and guinea pig TSPO and schematic membrane topology of the rat protein. Panel A, alignment of the rat, mouse and guinea
pig TSPO sequences. Panel B, schematic view of rat TSPO [38] where the methionine at position 113 is highlighted. For explanation see text.
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